Abstract P6-08-03: Dynamics of cancer stem cell surface marker, CD44 and CD44v6 in the antitumor efficacy of PARP inhibitor in combination with PI3K pathway inhibitor in TNBC xenograft model
Xiaoti Lin(Avera Health), Brian Leyland‐Jones(Avera Health), Yuchuan Sun(Avera Health), N Dey(Avera Health), JH Carlson(Avera Health), LS Friedman(Avera Health), Pradip De(University of South Dakota), Amy Krie(Amgen (United States))
Cited by 0
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
|Nature Medicine|2019|726
RET rearrangements are actionable alterations in breast cancer
|Nature Communications|2018|127
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
|JAMA Oncology|2021|110
Enrichment of PI3K-AKT–mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
|Clinical Cancer Research|2017|97